Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

This study is being done to evaluate the safety, tolerability and satisfactory relief of tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy.

Inclusion Criteria:

• History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years
• GI symptoms for at least 2 months before entering study

Exclusion Criteria:

• Very high body weight
• Significant diarrhea
• Ulcers

Symptom severity score collected via diary Other protocol-defined inclusion/exclusion criteria may apply.